3-溴-4-甲基-5-硝基苯甲酸 | 34545-20-5

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-溴-4-甲基-5-硝基苯甲酸
• 英文名称: 3-bromo-4-methyl-5-nitro-benzoic acid
• 英文别名: 3-bromo-4-methyl-5-nitrobenzoic acid；5-bromo-4-methyl-3-nitrobenzoic acid；3-Brom-4-methyl-5-nitro-benzoesaeure；5-Brom-3-nitro-p-toluylsaeure
• CAS: 34545-20-5
• 化学式: C₈H₆BrNO₄
• mdl: MFCD02041260
• 分子量: 260.044
• InChiKey: JEOLKHVBUQVYCK-UHFFFAOYSA-N

物化性质

• 沸点：
  387.0±42.0 °C(Predicted)
• 密度：
  1.777±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3-溴-4-甲基-5-硝基苯甲酸 在 platinum on activated charcoal 甲酸 、 三乙胺 、 diphenylammonium triflate 作用下， 以 甲苯 为溶剂， 反应 21.0h， 生成 2-[2-(2-methoxy-ethoxy)-ethoxy]-ethyl 3-amino-5-bromo-4-methyl-benzoate
  参考文献：
  名称：

  Solid-Phase Synthesis of m-Phenylene Ethynylene Heterosequence Oligomers

  摘要：

  Both homo- and heterosequence m-phenylene ethynylene oligomers are synthesized using a conceptually simple iterative solid-phase strategy. Oligomers are attached to Merrifield's resin through a known triazene-type linkage. The phenylene ethynylene molecular backbone is constructed through a series of palladium-mediated cross-coupling reactions. The strategy employs two types of monomers that bear orthogonal reactivity, one being a monoprotected bisethynyl arene and the other being a 3-bromo-5-iodo arene. The catalyst conditions are tailored to the requirements of each monomer type. The monoprotected bisethynyl arene is coupled to the growing chain in 2 h at room temperature using a Pd(I) dimer precatalyst ((Bu3P)-Bu-t-(Pd(mu-Cl)(mu-2-methyl allyl) Pd)(PBu3)-Bu-t) in conjunction with ZnBr2 and diisopropylamine. In alternate steps, the resin is deprotected in situ with TBAF and coupled to the 3-bromo-5-iodo arene using the iodo selective Pd(tri-2-furylphosphine) 4 catalyst in conjunction with CuI and piperidine; this reaction is also completed in 2 h at room temperature. These cross-coupling events are alternated until an oligomer of the desired length is achieved. The oligomer is then cleaved from the resin using CH2I2/I-2 at 110 degrees C and purified using preparatory GPC. Using this method, a series of homo- and heterosequence oligomers up to 12 units in length in excellent yield and purity were synthesized on the 100 mg scale. Longer oligomers were attempted; however, deletion sequences were found in oligomers longer than 12 units.

  DOI：

  10.1021/jo0607212
• 作为产物：
  描述：

  4-甲基-3-硝基苯甲酸 在 potassium bromate 、 硫酸 作用下， 以 水 为溶剂， 以85 %的产率得到3-溴-4-甲基-5-硝基苯甲酸
  参考文献：
  名称：

  环取代氯化苄在水溶液中溶剂解反应机理和过渡态结构的变化

  摘要：

  报告了 27 种单、二 [3,4] 和三 [3,4,5] 环取代的苄基氯的溶剂分解反应的速率和产物数据。 20% 乙腈水溶液中溶剂分解的一级速率常数从k解决= 2.2 秒−1 4-甲氧基苄基氯为 1.1 × 10 −8 s −1为3,4-二硝基氯苄。产物速率常数比k甲醇/ k四氟乙烯对于 70/27/3 (v/v/v) HOH/TFE/MeOH 范围内的溶剂分解，最低为k甲醇/ k四氟乙烯= 8 到最大 110。速率数据符合四参数哈米特方程，该方程分离了芳环取代基对反应速率的共振 () 和极性 () 影响。随着取代基常数 或 的增加，观察到哈米特反应常数 和 的值的增加。产品选择性急剧下降k甲醇/ k四氟乙烯= 26 4-甲氧基苄基氯的逐步溶剂分解被观察为吸电子元-由于溶剂加成到取代的 4-甲氧基苯甲基碳阳离子反应中间体的过渡态位置上的哈蒙德效应，取代基被添加到 4-甲氧基苯甲基环上。 选择性急剧增加k甲醇/

  DOI：

  10.1002/poc.4600

文献信息

• [EN] PROLYL HYDROXYLASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROLYL HYDROXYLASE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010059549A1

  公开（公告）日：2010-05-27

  The invention described herein relates to certain 2,4-dioxo-l,2,3,4-tetrahydro-7- quinazolinecarboxamide derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

  本发明涉及某些公式（I）的2,4-二氧代-1,2,3,4-四氢-7-喹唑啉羧酰胺衍生物，这些衍生物是HIF脯氨酸羟化酶的拮抗剂，对于治疗受益于抑制该酶的疾病是有用的，贫血就是一个例子。
• [EN] CARBOXY SUBSTITUTED (HETERO) AROMATIC RING DERIVATIVES AND PREPARATION METHOD AND USES THEREOF<br/>[FR] DÉRIVÉS DE CYCLE (HÉTÉRO) AROMATIQUE SUBSTITUÉS PAR CARBOXY ET PROCÉDÉS DE PRÉPARATION ET UTILISATIONS ASSOCIÉS
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2017036404A1

  公开（公告）日：2017-03-09

  Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine oxidase and urate anion transporter 1, and also can be used in the treatment or prevention of diseases associated with high blood uric acid level in mammals, especially humans.

  提供了含有羧基取代的(杂)芳基衍生物、包括这些化合物的药物组合物，以及制备这些化合物和组合物的方法。这些化合物或组合物在抑制黄嘌呤氧化酶和尿酸阴离子转运蛋白1方面具有用途，并且还可用于治疗或预防与高血尿酸水平有关的疾病，特别是人类。
• [EN] SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE<br/>[FR] INHIBITEURS SÉLECTIFS DE MUTANTS CLINIQUEMENT IMPORTANTS DE LA TYROSINE KINASE DE L'EGFR
  申请人：CS PHARMATECH LTD

  公开号：WO2019010295A1

  公开（公告）日：2019-01-10

  The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof, or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof, and methods and compositions for treating or ameliorating abnormal cell proliferative disorders, such as cancer, wherein A, R2, R3, R10, E1, E2, E3, Y, and Z are as defined herein.

  本发明提供了式（I）的化合物或其亚类结构或种属，或其药学上可接受的盐、酯、溶剂化合物和/或前药，以及用于治疗或改善异常细胞增殖性疾病，如癌症的方法和组合物，其中A、R2、R3、R10、E1、E2、E3、Y和Z如本文所定义。
• [EN] COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS COMME INHIBITEURS DE PROTÉINES KINASES
  申请人：ZHEJIANG BETA PHARMA INC

  公开号：WO2011038579A1

  公开（公告）日：2011-04-07

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Flt3, PDGFR, PDGFR, c-KIT, VEGFR1, VEGFR2, VEGFR3, c- RAF, AbI, Bcr-Abl, Aurora- A, AxI, BMX, CHK2, CSR0, Fes, FGFRi, FGFR3, IKKa, IR, JNK2a2, Lck, Met, MKK6, MST2, p70S6K, PKA, PKD2, ROCK-II, Ros, Rskl, SAPK2a, SAPK2ss, SAPK3 SAPK4, Syk, Tie2, TrkA and/or TrkB Kinases.

  这项发明提供了一类新型化合物，包括这种化合物的药物组合物以及使用这种化合物来治疗或预防与异常或失调的激酶活性相关的疾病或紊乱的方法，特别是涉及Flt3、PDGFR、PDGFR、c-KIT、VEGFR1、VEGFR2、VEGFR3、c-RAF、AbI、Bcr-Abl、Aurora-A、AxI、BMX、CHK2、CSR0、Fes、FGFRi、FGFR3、IKKa、IR、JNK2a2、Lck、Met、MKK6、MST2、p70S6K、PKA、PKD2、ROCK-II、Ros、Rskl、SAPK2a、SAPK2ss、SAPK3、SAPK4、Syk、Tie2、TrkA和/或TrkB激酶的异常激活的疾病或紊乱。
• Prolyl Hydroxylase Inhibitors
  申请人：Gotchev Dimitar B.

  公开号：US20100298324A1

  公开（公告）日：2010-11-25

  The invention described herein relates to certain 4-oxo-2-thioxo-1,2,3,4-tetrahydro-7-quinazolinecarboxamide derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

  本发明涉及一些公式（I）所示的4-氧代-2-硫代-1，2，3，4-四氢-7-喹唑啉羧酰胺衍生物，它们是HIF脯氨酸羟化酶的拮抗剂，并且用于治疗受益于抑制该酶的疾病，贫血是其中的一个例子。